Oncoinvent’s CEO to BioStock: “Radiopharmaceuticals has emerged as the hottest space in oncology”
Radiopharmaceuticals is a hot and emerging area that has attracted great interest from big pharma and investors in 2023, with several successful capital raises, IPOs and deals. A Nordic company within the field is Oncoinvent, based in Oslo and with lead candidate Radspherin in clinical development for the treatment of metastases in the peritoneal cavity from ovarian cancer and colorectal cancer.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se